Reduced Tumorigenicity and Pathogenicity of Cervical Carcinoma SiHa Cells Selected for Resistance to Cidofovir

Overview

Journal Mol Cancer

Publisher Biomed Central

Specialties Molecular Biology
Oncology

Date 2013 Dec 12

PMID 24325392

Citations 4

Authors

Tim De Schutter

Graciela Andrei

Dimitri Topalis

Sophie Duraffour

Tania Mitera

Joost van den Oord

Patrick Matthys

Robert Snoeck

Affiliations

Soon will be listed here.

Abstract

Background: Insights into the mechanisms associated with chemotherapy-resistance are important for implementation of therapeutic strategies and for unraveling the mode of action of chemotherapeutics. Although cidofovir (CDV) has proven efficacious in the treatment of human papillomavirus (HPV)-induced proliferation, no studies concerning the development of resistance to CDV in HPV-positive tumor cells have been performed yet.

Methods: From the cervical carcinoma SiHa cells (SiHaparental), which are HPV-16 positive, cidofovir-resistant cells (SiHaCDV) were selected, and differential gene expression profiles were analyzed by means of microarrays. We examined in vitro phenotyping of resistant cells compared to parental cells as well as tumorigenicity and pathogenicity in a mouse-xenograft model.

Results: SiHaCDV had a resistant phenotype and a reduced growth both in vitro and in vivo. A markedly diminished inflammatory response (as measured by production of host- and tumor-derived cytokines and number of neutrophils and macrophages in spleen) was induced by SiHaCDV than by SiHaparental in the xenograft model. Gene expression profiling identified several genes with differential expression upon acquisition of CDV-resistance and pointed to a diminished induction of inflammatory response in SiHaCDV compared to SiHaparental.

Conclusions: Our results indicate that acquisition of resistance to cidofovir in SiHa cells is linked to reduced pathogenicity. The present study contributes to our understanding on the antiproliferative effects of CDV and on the mechanisms involved, the inflammatory response playing a central role.

Citing Articles

LPS combined with CD47mAb enhances the anti‑osteosarcoma ability of macrophages.

Yuan P, Que Y, Liu Y, He P, Guo Z, Hu Y Oncol Lett. 2023; 25(5):190.

PMID: 37065782 PMC: 10091190. DOI: 10.3892/ol.2023.13777.

Resistance to the nucleotide analogue cidofovir in HPV(+) cells: a multifactorial process involving UMP/CMP kinase 1.

Topalis D, Nogueira T, De Schutter T, El Amri C, Krecmerova M, Naesens L Oncotarget. 2016; 7(9):10386-401.

PMID: 26824416 PMC: 4891127. DOI: 10.18632/oncotarget.7006.

Tumor-Suppressor Gene NBPF1 Inhibits Invasion and PI3K/mTOR Signaling in Cervical Cancer Cells.

Qin Y, Tang X, Liu M Oncol Res. 2016; 23(1-2):13-20.

PMID: 26802646 PMC: 7842551. DOI: 10.3727/096504015X14410238486766.

The broad-spectrum anti-DNA virus agent cidofovir inhibits lung metastasis of virus-independent, FGF2-driven tumors.

Liekens S, Noppen S, Gijsbers S, Sienaert R, Ronca R, Tobia C Oncotarget. 2015; 6(7):4633-48.

PMID: 25609197 PMC: 4467104. DOI: 10.18632/oncotarget.3079.

References

Wagh P, Peace B, Waltz S . Met-related receptor tyrosine kinase Ron in tumor growth and metastasis. Adv Cancer Res. 2008; 100:1-33. PMC: 4102433. DOI: 10.1016/S0065-230X(08)00001-8. View

De Schutter T, Andrei G, Topalis D, Duraffour S, Mitera T, Naesens L . Cidofovir treatment improves the pathology caused by the growth of human papillomavirus-positive cervical carcinoma xenografts in athymic nude mice. Cancer Lett. 2012; 329(2):137-45. DOI: 10.1016/j.canlet.2012.10.036. View

Ding P, An X, Zhang R, Fang Y, Li L, Chen G . Elevated preoperative neutrophil to lymphocyte ratio predicts risk of recurrence following curative resection for stage IIA colon cancer. Int J Colorectal Dis. 2010; 25(12):1427-33. DOI: 10.1007/s00384-010-1052-0. View

Iseri O, Demirel Kars M, Arpaci F, Gunduz U . Gene expression analysis of drug-resistant MCF-7 cells: implications for relation to extracellular matrix proteins. Cancer Chemother Pharmacol. 2009; 65(3):447-55. DOI: 10.1007/s00280-009-1048-z. View

Ihle J, Witthuhn B, Quelle F, Yamamoto K, Thierfelder W, Kreider B . Signaling by the cytokine receptor superfamily: JAKs and STATs. Trends Biochem Sci. 1994; 19(5):222-7. DOI: 10.1016/0968-0004(94)90026-4. View

Stragier I, Snoeck R, De Clercq E, van den Oord J, Van Ranst M, De Greef H . Local treatment of HPV-induced skin lesions by Cidofovir. J Med Virol. 2002; 67(2):241-5. DOI: 10.1002/jmv.2213. View

Solyanik G . Multifactorial nature of tumor drug resistance. Exp Oncol. 2011; 32(3):181-5. View

Deshpande A, Nolan J, White P, Valdez Y, Hunt W, Peyton C . TNF-alpha promoter polymorphisms and susceptibility to human papillomavirus 16-associated cervical cancer. J Infect Dis. 2005; 191(6):969-76. DOI: 10.1086/427826. View

Andrei G, Gammon D, Fiten P, De Clercq E, Opdenakker G, Snoeck R . Cidofovir resistance in vaccinia virus is linked to diminished virulence in mice. J Virol. 2006; 80(19):9391-401. PMC: 1617232. DOI: 10.1128/JVI.00605-06. View

10.

Schmidt H, Suciu S, Punt C, Gore M, Kruit W, Patel P . Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial. J Clin Oncol. 2007; 25(12):1562-9. DOI: 10.1200/JCO.2006.09.0274. View

11.

Liekens S, Andrei G, Vandeputte M, De Clercq E, Neyts J . Potent inhibition of hemangioma formation in rats by the acyclic nucleoside phosphonate analogue cidofovir. Cancer Res. 1998; 58(12):2562-7. View

12.

Chen R, Alvero A, Silasi D, Steffensen K, Mor G . Cancers take their Toll--the function and regulation of Toll-like receptors in cancer cells. Oncogene. 2008; 27(2):225-33. DOI: 10.1038/sj.onc.1210907. View

13.

Tamiya T, Kashiwagi I, Takahashi R, Yasukawa H, Yoshimura A . Suppressors of cytokine signaling (SOCS) proteins and JAK/STAT pathways: regulation of T-cell inflammation by SOCS1 and SOCS3. Arterioscler Thromb Vasc Biol. 2011; 31(5):980-5. DOI: 10.1161/ATVBAHA.110.207464. View

14.

Balkwill F, Mantovani A . Cancer-related inflammation: common themes and therapeutic opportunities. Semin Cancer Biol. 2012; 22(1):33-40. DOI: 10.1016/j.semcancer.2011.12.005. View

15.

Trecul A, Morceau F, Dicato M, Diederich M . Dietary compounds as potent inhibitors of the signal transducers and activators of transcription (STAT) 3 regulatory network. Genes Nutr. 2012; 7(2):111-25. PMC: 3316753. DOI: 10.1007/s12263-012-0281-y. View

16.

Wang M, Lao W, Wang D, Luo Y, Yao H . Blocking tumorigenic activities of colorectal cancer cells by a splicing RON receptor variant defective in the tyrosine kinase domain. Cancer Biol Ther. 2007; 6(7):1121-9. DOI: 10.4161/cbt.6.7.4337. View

17.

Qian B, Pollard J . Macrophage diversity enhances tumor progression and metastasis. Cell. 2010; 141(1):39-51. PMC: 4994190. DOI: 10.1016/j.cell.2010.03.014. View

18.

De Clercq E . Acyclic nucleoside phosphonates: past, present and future. Bridging chemistry to HIV, HBV, HCV, HPV, adeno-, herpes-, and poxvirus infections: the phosphonate bridge. Biochem Pharmacol. 2006; 73(7):911-22. DOI: 10.1016/j.bcp.2006.09.014. View

19.

De Clercq E . The acyclic nucleoside phosphonates from inception to clinical use: historical perspective. Antiviral Res. 2006; 75(1):1-13. DOI: 10.1016/j.antiviral.2006.10.006. View

20.

Camp E, Liu W, Fan F, Yang A, Somcio R, Ellis L . RON, a tyrosine kinase receptor involved in tumor progression and metastasis. Ann Surg Oncol. 2005; 12(4):273-81. DOI: 10.1245/ASO.2005.08.013. View